89 results about "Tight junction" patented technology

The invention belongs to the technical field of cytotoxicity intervention, and particularly relates to application of an iNOS inhibitor in preparation of a medicine for relieving cellular injury caused by toxin combined exposure. KK-1 cells serve as a research model, it is shown for the first time that MC-LR and NaNOS combined contamination can remarkably up-regulate the expression level of iNOS protein, and it is found through tests that Nos2 gene silencing can remarkably relieve tight junction damage and cell apoptosis caused by toxin combined exposure in the KK-1 cells; it is revealed for the first time that iNOS is a core target of toxin combined exposure induced cell tight junction damage and apoptosis, and the blank of toxic mechanism research in toxin combined exposure is filled. The application provides a new direction for a detoxification strategy of environmental toxin combined exposure, provides a theoretical basis for developing an iNOS-targeted inhibitor, and also provides a new target for etiological recognition, early diagnosis and prevention of related diseases caused by environmental toxin combined exposure.

The invention provides a method for evaluating the hemorrhagic disease resistance of grass carp based on intestinal mucosal barrier multi-dimensional indexes, and relates to the field of aquaculture and molecular biology. According to the method, grass carps with different genetic backgrounds are taken as objects, and comparison shows that after GCRV infection for 48 hours, the intestinal mucosa permeability of gynogenetic grass carps and disease-resistant grass carps is remarkably lower than that of common grass carps, the intestinal mucosa villus length is remarkably higher than that of the common grass carps, and the expression of intestinal mucosa tight junction molecules is remarkably higher than that of the common grass carps; expression of intestinal mucosa immune related factors is obviously higher than that of common grass carp, diversity and abundance of intestinal flora are obviously higher than that of common grass carp, concentration of four key antioxidant enzymes in serum is obviously higher than that of common grass carp, and content of liver and intestinal VP56 is obviously lower than that of common grass carp. Therefore, after 15 days of GCRV infection, the survival rate of gynogenesis grass carps and disease-resistant grass carps is significantly higher than that of common grass carps. The invention provides a novel method for evaluating the hemorrhagic disease resistance of the grass carp.

To provide a novel agent capable of reinforcing tight junctions to improve the barrier function of the skin.SOLUTION: The inventors have paid attention to short-chain fatty acids, which had been considered unsuitable for use in cosmetics and the like, and conducted extensive research and discovered that acetic acid, propionic acid, and lactic acid, which are short-chain fatty acids, lower transepidermal water loss (TEWL) in a three-dimensional skin model. This invention provides a skin barrier function improver containing short-chain fatty acids as an active ingredient.SELECTED DRAWING: Figure 1

A synthetic is disclosed. The synthetic tissue comprises a colony of modified single celled organisms; and a protein produced by the modified single cell organism. The modified single cell organism may be modified by a plasmid. The protein may resemble at least one protein of the collection of proteins known as tight junction or another cell-to-cell adhesion protein. A region of the protein that resembles a specific region of a cell-to-cell adhesion protein may link to the same region of other proteins using linker regions. The region of the protein that resembles the specific region of a cell-to-cell adhesion protein may resemble a protein of the outer cell membrane of the single cell organisms in the colony of single cell organisms.

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

To provide a novel compound capable of controlling tight junctions.SOLUTION: A tight junction control agent comprising at least one selected from the compounds represented by formulas (1) to (4), or at least one selected from pharmaceutically acceptable salts of the compounds represented by formulas (1) to (4).SELECTED DRAWING: Figure 4

The invention discloses application of rosmarinic acid and a derivative thereof as a tight connection relaxation agent. The rosmarinic acid and the derivative thereof are competitively combined with the PDZ-1 structural domain of the ZO-1 protein, connection of Claudins protein between epithelial cells is reversibly relaxed, the ability of active substances penetrating epithelial tissues of skin, small intestines and the like is safely and efficiently improved, and the rosmarinic acid and the derivative thereof can be applied to the fields of medicines, foods, cosmetics and the like.

The invention discloses an application of a CTSS inhibitor in preparation of a medicine for regulating a blood-cerebrospinal fluid barrier. Wherein the CLDN1 between the CTSS in the CP and the CPECs is inversely correlated, then the CLDN1 is confirmed to be damaged after being processed by the CTSS, and correlation exists through CTSS-CLDN1-CP epithelial cell tight connection-CP aging, so that the CTSS can be applied to predict whether the CLDN1 is damaged and tightly connected or not, and then whether a B-CSF barrier is damaged or not or whether the B-CSF barrier is more permeable or not is detected.

The present invention discloses the preparation of patchouli flavonoid nanoliposomes and their application in inhalation treatment of acute lung injury, and relates to the field of medical technology. The patchouli flavonoid nanoliposomes provided by the present invention prepare patchouli flavonoids into a liposome dosage form, which has good stability and biocompatibility. The drug is administered to mice with acute lung injury, so that patchouli flavonoids can act on the mouse lungs in a targeted manner, reduce the expression of inflammatory factors such as IL-6, IL-1β and TNF-α in the mouse lungs to relieve inflammation, improve pulmonary edema, and reduce lung tissue damage, while increasing the levels of tight junction factors such as ZO-1, VE-Cadherin, E-Cadherin and Claudin5 to repair lung barrier damage. The present invention is expected to provide an effective strategy for the treatment of acute lung injury.

The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof, and relates to the technical field of medicines.The application discloses a human vagina micro-ecological in-vitro model and a construction method and application thereof.Firstly, a mixed cell group of the vaginal epithelium containing a complete cell lineage and capable of long-term subculture is successfully established, a technical bottleneck that primary vaginal epithelial cells are difficult to expand is solved, and ideal seed cells are provided for model construction.Secondly, a highly-bionic vaginal mucosa model having a tight connection structure, rich layers and an orderly arrangement is constructed, and the physiological barrier and immune regulation functions of the vaginal mucosa are truly simulated.Finally, by introducing lactobacillus symbiosis and confirming the response to estrogen, a multi-element in-vitro research model integrating the anatomical structure of the vagina, resident flora, local immunity and endocrine regulation is constructed, and a reliable technical platform is provided for in-depth exploration of the mechanism of vaginal micro-ecological disorder and efficient screening of related drugs.

The present application relates to the technical field of medicine, in particular to a kind of siRNA eye drop for penetrating mucus barrier and cell barrier and preparation method thereof.Innovative development side chain guanidino group-containing polydisulfide delivery carrier is used in the present application, through the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on mucin, tear film retention and efficient penetration are realized, and cationic polydisulfide is quickly adsorbed on the surface of negative charged cell membrane by electrostatic interaction, the quick dynamic disulfide exchange reaction between polydisulfide and sulfhydryl on cell membrane is used, and endocytosis is used to quickly penetrate tight junction cell layer.

The invention relates to the technical field of microorganisms, in particular to application of plant lactobacillus BD7807 in preparation of a product for treating intestinal barrier dysfunction. The product for treating intestinal barrier dysfunction can significantly improve Caco2 cell monolayer barrier injury induced by excessive fatty acid, alleviate body oxidative stress injury and whole body chronic low-degree inflammation caused by high fat diet, significantly enhance expression of tight junction genes and activity of proteins, enhance integrity of intestinal epithelial barrier, and improve the intestinal barrier dysfunction. And the market prospect is wide.

The invention discloses an oral drug delivery system with a double-emulsion structure and application of the oral drug delivery system in preparation of drugs for treating premature ovarian insufficiency, and belongs to the technical field of biological medicines. The oral drug delivery system comprises droplet particles formed by wrapping an MSCs conditioned culture medium with an oil-phase solvent, and exosomes uniformly distributed on the outer surfaces of the droplet particles, so that a double-emulsion structure is formed. Water-soluble MSC-CM is wrapped by a water-in-oil-in-water method to form a double-emulsion structure, so that water-soluble protein enters a human body to be absorbed in an oral manner. The MSC-CM composite has good structural stability and viscoelasticity, the particle size range is about 10-50 microns, contact with intestinal epithelial cells can be increased, meanwhile, the skeleton of the intestinal epithelial cells can be changed, expression of tight junction protein of the intestinal epithelial cells can be lowered, tight junction barriers of the intestinal epithelial cells can be opened, and therefore the bioavailability of MSC-CM is improved, and the MSC-CM composite has a good application prospect. The effect of treating the POI is achieved.

Compositions for promoting intestinal health are disclosed and described. In one example, the composition can include a combination of cyanidins and delphinidins, in an amount sufficient to treat intestinal hyperpermeability. In a further example, the composition can further comprise a prebiotic blend and fructooligosaccharides. Further presented herein, is a method of treating a condition or disorder related to gastrointestinal health in a subject. In one example, the method can include maximizing tight junction integrity in epithelial cells of gastrointestinal tract of the subject.

The application discloses application of butyric acid in preparation of a medicine for treating oral ulcer, and belongs to the field of biological medicine. The butyric acid plays a therapeutic effect by increasing expression of tight junction proteins in oral mucosa tissue, reducing inflammatory reaction and promoting healing of oral ulcer. The application uses butyric acid to treat oral ulcer, evaluates the curative effect of butyric acid and explores the corresponding internal mechanism. The results show that the butyric acid has obvious effect in treating oral ulcer caused by chemotherapy, and provide a scientific basis for clinical application of butyric acid.

The present invention provides a recombinant type IV collagen composition for repairing basement membrane and soothing and reducing redness. The inventors found that the recombinant type IV collagen described in the specification of this patent inhibits the phosphorylation of VE-cadherin protein by mediating the PKCα / PYK2 / Src signaling pathway, protects the tight junctions between endothelial cells, prevents the leakage of blood components, and reduces vascular permeability; it can also improve the dissociation of the VE-cadherin complex caused by oxidative stress and maintain the homeostasis of the endothelial barrier; therefore, it has good effects of repairing the basement membrane barrier and soothing and reducing redness. The inventors also first discovered that the repair peptide (GAAGLPGPK) has the effects of repairing the basement membrane barrier, soothing and reducing redness, and the combination of a certain proportion of the recombinant type IV collagen and the repair peptide shows synergistic effects in repairing the basement barrier and soothing and reducing redness.

Present invention relates to a method of treating a disorder by administering an effective amount of a pharmaceutical composition comprising a therapeutic agent bound to a p80 neurotoxin associated polypeptide (NAP) derived from Clostridium Botulinum Type E (BoNT / E). The p80 is bound to a therapeutic agent, comprising one or more of: drugs, dyes, small molecules, biomolecules, proteins or a combination thereof. P80 enhances the transportation of the therapeutic agent into the bloodstream for increased bioavailability because thep80 is a tight junction modulator to enhance the permeability of the intestinal epithelium so as to facilitate drug delivery.

The invention discloses application of burdock polysaccharide in relieving motor ability decline and intestinal flora disorder caused by acute sleep deprivation, and belongs to the field of medical biology. The invention verifies the influence of the burdock polysaccharide on motor ability reduction, intestinal flora homeostasis and function reduction caused by acute sleep deprivation, and also verifies the relationship of the burdock polysaccharide on motor ability, body energy metabolism and intestinal flora of an acute sleep deprivation individual and a potential mediation mechanism of the burdock polysaccharide in an intestinal-muscle axis. According to the invention, burdock polysaccharide is used on an acute sleep deprivation model, and the application of burdock polysaccharide in treating motor ability and intestinal injury after acute sleep deprivation is verified. Through athletic ability, energy metabolism, inflammatory factors in serum, oxidative stress in liver and Hamp of ileum tissue; e staining, expression of tight junction protein and determination of indexes such as intestinal flora and the like find that the burdock polysaccharide can effectively improve the athletic ability and the intestinal flora after acute sleep deprivation.

The invention provides a pharmaceutical composition for protecting intestinal injury caused by chemotherapy and application, and belongs to the field of medicines. The invention also provides a pharmaceutical composition for protecting intestinal mucosa tight junction injury caused by chemotherapy. The pharmaceutical composition is prepared from the following raw material medicines in parts by weight: 1-3 parts of astragalus polysaccharide and 1-3 parts of ziyuglycoside I. According to the invention, the compatibility of astragalus polysaccharide and ziyuglycoside I not only can improve the immunity of the organism after chemotherapy, but also can protect intestinal mucosal injury caused by intestinal chemotherapy drugs, and solves the problem that no special-effect drug for intestinal injury after chemotherapy exists in the current market, and pharmacodynamic tests prove that when the compatibility of astragalus polysaccharide and ziyuglycoside I is used, the curative effect is obvious. The intestinal mucosa tight junction injury caused by chemotherapy is protected, and the synergistic effect is achieved. The composition disclosed by the invention has the effects of protecting intestinal injury caused by pet chemotherapy or diarrhea of young animals, maintaining the integrity of the form and the structure of intestinal tissues, enhancing the immunity of the young animals, reducing the economic loss and reducing the use of antibiotics.

The application provides a pharmaceutical composition for protecting intestinal injury caused by chemotherapy and use, and belongs to the field of medicines. The application also provides a pharmaceutical composition for protecting tight junction injury of intestinal mucosa caused by chemotherapy, which is prepared from raw medicinal materials in the following proportions by weight: 1-3 parts of astragalus polysaccharide and 1-3 parts of sanguisorba officinalis saponin I. The astragalus polysaccharide combined with the sanguisorba officinalis saponin I can not only improve the immunity of the body after chemotherapy, but also protect the intestinal mucosa injury caused by intestinal chemotherapy drugs, and solves the problem that there is no specific drug for intestinal injury after chemotherapy on the market. The drug efficacy test proves that the astragalus polysaccharide combined with the sanguisorba officinalis saponin I has a synergistic effect on protecting the tight junction injury of intestinal mucosa caused by chemotherapy. The composition of the application can protect the intestinal injury of pets caused by chemotherapy or diarrhea of young animals, maintain the integrity of the intestinal tissue morphology and structure, enhance the immunity of young animals, reduce economic losses, and reduce the use of antibiotics.

This invention discloses a mixture of artemisia annua extract and rosemary extract and its application in the field of dermatology. The invention provides a mixture of artemisia annua extract and rosemary extract, a preparation method, and applications. This mixture can regulate the function of macrophages and epidermal cells, enhancing the phagocytic capacity of macrophages and initiating normal skin immune defense. Simultaneously, it can inhibit the overexpression of inflammatory factors, increase the expression of tight junction proteins in epidermal cells, and restore the skin barrier.

The invention discloses an indole derivative for promoting development of piglet intestinal stem cells, and particularly relates to application of indole-3-aldehyde in promoting development and growth performance of piglet intestinal epithelium. The indole-3-aldehyde can be used as a feed additive to be applied to a piglet creep feed and a nursing feed, promote the development of forms and functions of piglet intestinal stem cells and intestinal epithelium, improve the length and the index of the small intestine of the piglet and reduce the feed-weight ratio of the piglet. It is found that indole-3-aldehyde guarantees animal health and improves the growth performance of animals by adjusting proliferation and differentiation of piglet intestinal stem cells, increasing the number of goblet cells, up-regulating expression of tight junction protein, promoting intestinal epithelium development and intestinal barrier functions and promoting absorption and utilization of intestinal epithelium to nutrient substances.

The invention belongs to the technical field of food and medicine, and particularly relates to a protein compound for relieving intestinal inflammation and a preparation method and application thereof. The protein compound for relieving intestinal inflammation provided by the invention is mainly prepared by compounding milk-derived osteopontin (OPN) and alpha-lactalbumin (alpha-LA). Compared with single OPN or alpha-LA, the protein complex provided by the invention shows a remarkable effect of promoting proliferation of intestinal epithelial cells, and effectively improves the physical barrier function of intestinal tracts and relieves intestinal inflammation damage caused by lipopolysaccharide by enhancing expression of tight junction protein. Therefore, the invention proves that the OPN-alpha-LA compound has a remarkable effect of relieving intestinal inflammation, which not only is beneficial to promoting the in-depth study of OPN and the compound thereof in regulating intestinal mucosal immunity in the functional protein field, but also can lay a scientific foundation for developing novel functional foods or novel enteritis medicines by using the active protein as a raw material.

This invention relates to the fields of biomedicine and food nutrition, specifically to the application of purple sweet potato anthocyanins in the preparation of products for preventing or improving intestinal aging. This invention demonstrates that purple sweet potato anthocyanins can significantly improve the degenerative changes and barrier fragility of the colon caused by natural aging, restore colonic crypt morphology and epithelial ultrastructure, and upregulate the expression of tight junction proteins and mucus barrier-related indicators. Furthermore, purple sweet potato anthocyanins can effectively enhance crypt proliferation activity and promote the differentiation of intestinal stem cells into secretory lineages (such as goblet cells and enteroendocrine cells). Its mechanism of action does not rely on direct anti-inflammatory pathways, but rather on remodeling intestinal flora metabolism (such as increasing short-chain fatty acids) and activating intestinal cell autophagy via the PI3K-Akt signaling pathway, thereby supporting the continuous renewal and maintenance of the intestinal barrier. This invention provides a new approach for the development and application of food-derived polyphenols targeting the gut to promote healthy aging.

Formulations, are used for eye treatments, e.g., cross-linking treatments. For example, a therapeutic formulation includes a photosensitizer and delivery agent(s), wherein the delivery agent(s) include at least one of: anesthetic agent(s), analgesic agent(s), tonicity agent(s), or shear-thinning, or viscosity-increasing agent(s). In another example, a method includes applying preparatory formulation(s) to increase a permeability of a corneal epithelium, and applying therapeutic formulation(s) to the epithelium, where the preparatory formulation(s) include zinc metalloproteinase, copper metalloproteinase, papain, bromelain, actinidin, ficain, N-acetylcysteine, ambroxol, carbocisteine, and / or erdosteine. In yet another example, a method includes applying therapeutic formulation(s) to a corneal epithelium to deliver the therapeutic formulation(s) to a stroma, and applying enhancement formulation(s) to the epithelium in response to applying the therapeutic formulation(s), where: the enhancement formulation(s) remove the therapeutic formulation(s) from the epithelium; close tight junctions of the epithelium; promote oxidation for the therapeutic agent(s); and / or further deliver the therapeutic formulation(s) to the stroma.

The invention discloses an active substance for repairing a cat sensitization type barrier and a preparation method and application thereof, and relates to the technical field of animal health care products. The cat feed additive comprises one or more of heartleaf houttuynia herb extract, green tea polyphenol, ginkgo leaf extract, glutamine, beta-glucan, linoleic acid, vitamin B6, vitamin B2 and the like, and the components jointly act on oxidative stress, inflammatory response and metabolic process of intestinal tracts and skin of cats. By measuring indexes such as inflammatory factors, oxidative stress and tight junction protein and combining in-vitro metabonomics and transcriptomics analysis, the pharmaceutical composition has remarkable effects in the aspects of oxidation resistance, inflammation resistance, mucosal barrier repair and the like. In addition, the invention also provides application of the active substance in preparation of food for repairing cat barrier dysfunction. Compared with the prior art, an effective health-care strategy can be provided, and cat barrier dysfunction can be remarkably repaired.

The method is for modulating tight junction (TJ) integrity in a subject. The method comprises (a) evaluating TJ integrity in a subject by quantifying at least one biomarker of TJ integrity in the subject; (b) administering the subject a first composition containing (i) at least one polyphenol and (ii) a second substance, rather than a polyphenol, that upregulates CAMP gene expression in the subject; (c) re-evaluating TJ integrity in the subject by quantifying at least one biomarker of TJ integrity in the subject; and (d) repeating steps (b) and (c) until the value of the at least one biomarker falls within the target range.

The present invention relates to a food composition comprising dead cells of Lactobacillus paracasei HY2782. The dead cells of Lactobacillus paracasei HY2782 of the present invention strengthens tight junctions, and thus can improve intestinal function.

The invention provides a collagen peptide-containing sebum membrane repairing composition and a preparation method thereof, and relates to the field of biomedical materials. The sebum film repairing composition is prepared from a recombinant III type collagen peptide, a recombinant I type collagen peptide, a ceramide compound, squalane, a natural moisturizing factor, glycosyl trehalose, phytosterol, glycerol, butanediol, polyglycerol-10 laurate, laurocapram and water. According to the sebum membrane repairing composition, the recombinant III-type collagen peptide and the recombinant I-type collagen peptide have a synergistic effect with the ceramide compound, so that the ceramide recovery rate is greatly improved, and the composition can realize'lipid barrier-aquaporin-tight connection 'three-in-one repairing of a sebum membrane.

The invention discloses a miR-144-3p inhibitor for relieving fish intestinal injury induced by oxidized fish oil and application, and belongs to the technical field of aquatic animal nutrition physiological regulation and control. The miR-144-3p inhibitor is injected into the intraperitoneal cavity of megalobrama amblycephala, transcription of an oxidative stress core regulatory element Nrf2 is up-regulated, overexpression of autophagy and apoptosis related genes induced by intake of oxidized fish oil is inhibited, damage of an intestinal tight junction structure is improved, and the active oxygen level and the autophagy and apoptosis level of intestinal cells are reduced. The method can quickly, efficiently and specifically relieve intestinal barrier injury, oxidative stress and intestinal cell apoptosis induced by oxidative rancidity of freshwater fish feed grease and the like, and healthy and efficient culture of freshwater fish is achieved.